2‐(オキサゾロ[5,4‐b]ピリジン‐2‐イル)ベンゾニトリル
分子式: | C13H7N3O |
その他の名称: | H-19、o-(Oxazolo[5,4-b]pyridin-2-yl)benzonitrile、2-(Oxazolo[5,4-b]pyridine-2-yl)benzonitrile |
体系名: | o-(オキサゾロ[5,4-b]ピリジン-2-イル)ベンゾニトリル、2-(オキサゾロ[5,4-b]ピリジン-2-イル)ベンゾニトリル |
H‐19
H19
出典: フリー百科事典『ウィキペディア(Wikipedia)』 (2022/11/04 04:54 UTC 版)
H19は、ヒトなどに存在する長鎖ノンコーディングRNAの遺伝子である。H19は体重と細胞増殖を負に調節する役割を持つ[3]。また、この遺伝子は一部のがんの形成や遺伝子発現の調節に関与している[4]。
- ^ a b c GRCh38: Ensembl release 89: ENSG00000130600、ENSG00000288237 - Ensembl, May 2017
- ^ Human PubMed Reference:
- ^ Gabory (2009). “H19 acts as a trans regulator of the imprinted gene network controlling growth in mice”. Development 136 (20): 3413–3421. doi:10.1242/dev.036061. PMID 19762426.
- ^ “H19: imprinted maternally expressed transcript (non-protein coding) (Homo sapiens)”. Entrez Gene. National Center for Biotechnology Information. 2008年6月6日閲覧。
- ^ “Monoallelic expression of the human H19 gene”. Nat. Genet. 1 (1): 40–44. (April 1992). doi:10.1038/ng0492-40. PMID 1363808.
- ^ “Parental imprinting of the human H19 gene”. FEBS Lett. 309 (1): 25–28. (August 1992). doi:10.1016/0014-5793(92)80731-U. PMID 1380925.
- ^ “The human ASM (adult skeletal muscle) gene: expression and chromosomal assignment to 11p15”. Biochem. Biophys. Res. Commun. 180 (3): 1241–1250. (November 1991). doi:10.1016/S0006-291X(05)81329-4. PMID 1953776.
- ^ Online 'Mendelian Inheritance in Man' (OMIM) H19 Gene -103280
- ^ a b c “Methylation loss at H19 imprinted gene correlates with methylenetetrahydrofolate reductase gene promoter hypermethylation in semen samples from infertile males”. Epigenetics 8 (9): 990–997. (September 2013). doi:10.4161/epi.25798. PMC 3883776. PMID 23975186 .
- ^ a b c d “Establishment of functional imprinting of the H19 gene in human developing placentae”. Nat. Genet. 10 (3): 318–324. (July 1995). doi:10.1038/ng0795-318. PMID 7670470.
- ^ a b “The effect of retinoic acid on the activation of the human H19 promoter by a 3' downstream region”. FEBS Lett. 432 (3): 123–127. (August 1998). doi:10.1016/S0014-5793(98)00841-2. PMID 9720909.
- ^ a b “Loss of H19 imprinting in adult T-cell leukaemia/lymphoma”. Br. J. Haematol. 137 (4): 380–381. (May 2007). doi:10.1111/j.1365-2141.2007.06581.x. PMID 17408396.
- ^ a b c “H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1”. J. Biol. Chem. 280 (33): 29625–29636. (August 2005). doi:10.1074/jbc.M504033200. PMID 15985428.
- ^ a b c d e f g “Ectopic expression of the H19 gene in mice causes prenatal lethality”. Genes Dev. 5 (6): 1092–1101. (June 1991). doi:10.1101/gad.5.6.1092. PMID 2044956.
- ^ a b c d “The product of the H19 gene may function as an RNA”. Mol. Cell. Biol. 10 (1): 28–36. (January 1990). doi:10.1128/MCB.10.1.28. PMC 360709. PMID 1688465 .
- ^ Juan, V.; Crain, C.; Wilson, C. (2000-03-01). “Evidence for evolutionarily conserved secondary structure in the H19 tumor suppressor RNA”. Nucleic Acids Research 28 (5): 1221–1227. doi:10.1093/nar/28.5.1221. ISSN 1362-4962. PMC PMC102599. PMID 10666466 .
- ^ Barciszewski, Jan (2003). Noncoding RNAs : molecular biology and molecular medicine. V. A. Erdmann. Georgetown, Tex.: Landes Bioscience/Eurekah.com. p. 85. ISBN 1-4175-7768-1. OCLC 58797276
- ^ a b c d e f g “An enhancer deletion affects both H19 and Igf2 expression”. Genes Dev. 9 (17): 2079–2089. (September 1995). doi:10.1101/gad.9.17.2079. PMID 7544754.
- ^ a b c d e “Association of IGF2 and H19 imprinting with choriocarcinoma development”. Cancer Genet. Cytogenet. 93 (1): 39–47. (January 1997). doi:10.1016/S0165-4608(96)00221-X. PMID 9062579.
- ^ a b c d e f g h “Characterization of human and mouse H19 regulatory sequences”. Mol. Biol. Rep. 27 (3): 157–165. (September 2000). doi:10.1023/A:1007139713781. PMID 11254105.
- ^ a b c d “H19 and IGF2 gene expression in human normal, hyperplastic, and malignant endometrium”. Int. J. Gynecol. Cancer 14 (3): 521–525. (2004). doi:10.1111/j.1048-891x.2004.014314.x. PMID 15228427.
- ^ a b c d “Steroid hormones modulate H19 gene expression in both mammary gland and uterus”. Oncogene 18 (31): 4460–4473. (August 1999). doi:10.1038/sj.onc.1202819. PMID 10442637.
- ^ a b c “Polyploidization of murine mesenchymal cells is associated with suppression of the long noncoding RNA H19 and reduced tumorigenicity”. Cancer Research 72 (24): 6403–6413. (December 2012). doi:10.1158/0008-5472.CAN-12-1155. PMID 23047867.
- ^ a b “Genomic imprinting in mammalian development: a parental tug-of-war”. Trends Genet. 7 (2): 45–49. (February 1991). doi:10.1016/0168-9525(91)90230-N. PMID 2035190.
- ^ a b c d e f g h i j “Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors”. J. Clin. Endocrinol. Metab. 87 (3): 1170–1176. (March 2002). doi:10.1210/jc.87.3.1170. PMID 11889182.
- ^ “CTCF regulates asynchronous replication of the imprinted H19/Igf2 domain”. Cell Cycle 6 (4): 450–454. (February 2007). doi:10.4161/cc.6.4.3854. PMID 17329968 .
- ^ “Loss of H19 imprinting in esophageal cancer”. Cancer Res. 56 (3): 480–482. (February 1996). PMID 8564957 .
- ^ a b c “Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells”. Carcinogenesis 23 (11): 1885–1895. (November 2002). doi:10.1093/carcin/23.11.1885. PMID 12419837.
- ^ a b “The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis”. Cancer Res. 66 (10): 5330–5337. (May 2006). doi:10.1158/0008-5472.CAN-06-0037. PMID 16707459.
- ^ a b “The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma”. FEBS Lett. 374 (1): 57–61. (October 1995). doi:10.1016/0014-5793(95)01074-O. PMID 7589512.
- ^ a b c d e Wölfl, Stefan, ed (2007). “The H19 non-coding RNA is essential for human tumor growth”. PLOS ONE 2 (9): e845. Bibcode: 2007PLoSO...2..845M. doi:10.1371/journal.pone.0000845. PMC 1959184. PMID 17786216 .
- ^ a b “The product of the imprinted H19 gene is an oncofetal RNA”. Mol. Pathol. 50 (1): 34–44. (February 1997). doi:10.1136/mp.50.1.34. PMC 379577. PMID 9208812 .
- ^ a b “Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer”. Eur. J. Obstet. Gynecol. Reprod. Biol. 85 (1): 7–11. (July 1999). doi:10.1016/S0301-2115(98)00275-9. PMID 10428315.
- ^ “Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinoma”. Oncogene 18 (50): 7063–7069. (November 1999). doi:10.1038/sj.onc.1203192. PMID 10597307.
- ^ a b c d e f g “H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein”. Cancer Res. 56 (13): 2904–2907. (July 1996). PMID 8674037 .
- ^ a b “Imprinted H19 gene expression in embryogenesis and human cancer: the oncofetal connection”. Am. J. Med. Genet. 91 (1): 46–50. (March 2000). doi:10.1002/(SICI)1096-8628(20000306)91:1<46::AID-AJMG8>3.0.CO;2-I. PMID 10751088.
- ^ a b “The imprinted H19 gene as a tumor marker in bladder carcinoma”. Urology 45 (2): 335–338. (February 1995). doi:10.1016/0090-4295(95)80030-1. PMID 7855987.
- ^ “Polymorphisms in the H19 Gene and the Risk of Bladder Cancer”. Eur. Urol. 54 (5): 1118–1126. (February 2008). doi:10.1016/j.eururo.2008.01.060. PMID 18262338.
- ^ a b c Adriaenssens, E.; Dumont, L.; Lottin, S.; Bolle, D.; Leprêtre, A.; Delobelle, A.; Bouali, F.; Dugimont, T. et al. (1998-11). “H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression”. The American Journal of Pathology 153 (5): 1597–1607. doi:10.1016/S0002-9440(10)65748-3. ISSN 0002-9440. PMC 1853398. PMID 9811352 .
- ^ “Breast Cell Line MCF-7”. Cancer Biology - Breast Cancer Cell Line Database. University of Texas M. D. Anderson Cancer Center. 2008年6月6日閲覧。
- ^ “The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen”. Cancer Res. 57 (24): 5460–5464. (December 1997). PMID 9407950 .
- ^ “Decreased sensitivity of carcinoembryonic antigen cDNA-transfected cells to adriamycin”. Int. J. Cancer 72 (2): 377–382. (July 1997). doi:10.1002/(SICI)1097-0215(19970717)72:2<377::AID-IJC29>3.0.CO;2-B. PMID 9219849.
- ^ “A prognostic multigene classifier for squamous cell carcinomas of the larynx”. Cancer Letters 307 (1): 37–46. (August 2011). doi:10.1016/j.canlet.2011.03.013. PMID 21481529.
- ^ Coorens, Tim H. H.; Treger, Taryn D.; Al-Saadi, Reem; Moore, Luiza; Tran, Maxine G. B.; Mitchell, Thomas J.; Tugnait, Suzanne; Thevanesan, Christine et al. (2019-12-06). “Embryonal precursors of Wilms tumor”. Science (New York, N.Y.) 366 (6470): 1247–1251. doi:10.1126/science.aax1323. ISSN 1095-9203. PMC 6914378. PMID 31806814 .
- ^ a b c d “Possible physiological role of H19 RNA”. Mol. Carcinog. 35 (2): 63–74. (October 2002). doi:10.1002/mc.10075. PMID 12325036.
- ^ a b c “Thioredoxin post-transcriptional regulation by H19 provides a new function to mRNA-like non-coding RNA”. Oncogene 21 (10): 1625–1631. (February 2002). doi:10.1038/sj.onc.1205233. PMID 11896592.
- ^ “Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma”. Cancer Lett. 119 (2): 143–148. (November 1997). doi:10.1016/S0304-3835(97)00264-4. PMID 9570364.
- ^ a b c d “Disruption of imprinting caused by deletion of the H19 gene region in mice”. Nature 375 (6526): 34–39. (May 1995). Bibcode: 1995Natur.375...34L. doi:10.1038/375034a0. PMID 7536897.
- ^ “The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma”. Mol. Pathol. 53 (6): 320–323. (December 2000). doi:10.1136/mp.53.6.320. PMC 1186987. PMID 11193051 .
- ^ “Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer”. ClinicalTrials.gov. U.S. National Institutes of Health (2009年8月31日). 2010年1月14日閲覧。
- ^ “Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer With Symptomatic Ascites”. ClinicalTrials.gov. U.S. National Institutes of Health (2009年12月3日). 2010年1月14日閲覧。
- ^ “Phase 1/2a DTA-H19 in Patients With Unresentable Pancreatic Cancer”. ClinicalTrials.gov. U.S. National Institutes of Health (2009年11月9日). 2010年1月14日閲覧。
- ^ a b “Phase I/II Marker Lesion Study of Intravesical BC-819 DNA Plasmid in H19 Over Expressing Superficial Bladder Cancer Refractory to Bacillus Calmette-Guerin”. The Journal of Urology 180 (6): 2379–2383. (December 2008). doi:10.1016/j.juro.2008.08.006. ISSN 0022-5347. PMID 18950807.
- H19のページへのリンク